CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.

Employees - 8, CEO - Rami Levin, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -43.11, Piotroski Score(max is 10): 1, Working Capital: $-531396, Total Assets: $4653192, Retained Earnings: $-105212314, EBIT: -16471157, Total Liabilities: $4582487, Revenue: $0

AryaFin Target Price - $15.5 - Current Price $ - Analyst Target Price $